Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TX000045- Dose A · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| TX000045- Dose A | DRUG | The participants will receive a subcutaneous injection of Dose A of TX000045 every 2 weeks for 24 weeks. |
| TX000045- Dose B | DRUG | The participants will receive subcutaneous injection of Dose B of TX000045 every 4 weeks for 24 weeks where they will alternate between TX000045 and placebo every 2 weeks. |
| Placebo | DRUG | The participants will receive a subcutaneous injection of placebo every 2 weeks for 24 weeks. |